Notícias

“No, I don’t think so,” answered Joon Sung Park, co-founder and CEO at “digital twin” startup Simile, on the opening day of the Leadership Institute’s WSJ Technology Council Summit yesterday. Twins created with Simile are currently helping CVS Health make decisions more quickly and confidently, executives said as part of the same discussion. When the pharmacy and insurance company wanted to encourage adoption of lower-cost biologic drug alternatives, twins of the consumer pool suggested that people wanted to hear recommendations from their healthcare providers, said Tilak Mandadi, executive vice president of ventures and chief experience and technology officer at CVS Health.

Tilak Mandadi, chief experience and technology officer at CVS Health, criticized the growing trend of appointing "Chief AI Officers," and explains what leaders should be focusing on instead.

At the WSJ Leadership Institute's Tech Council Summit, CVS Health’s Sri Narasimhan breaks down how AI simulations are disrupting traditional market research.

The health care giant showered its owners with cash, yet the stock spent years in the slow lane. Here’s the accounting of what that trade-off actually delivered.

Joon Sung Park, chief executive of AI startup Simile, and Tilak Mandadi and Sri Narasimhan of CVS Health discuss the practical applications, accuracy and enterprise potential of AI-driven human behavior simulations.

UnitedHealth (UNH) has spent the past year repairing margins rather than chasing growth. The shares rebounded well ahead of any actual margin recovery: up about 38% over the past six months, though down about 6% over the past three, and still behind the S&P 500 over the past twelve months, 12.2% for the stock against 18.6% for the index. What argues for owning them now shows up in cash running ahead of reported profit.

CVS Health is looking more attractive -- and it sports an appealing dividend, too, recently yielding 2.8%.

CVS is picking up the overflow as Walgreens closes 1,200 stores and goes private.

Older workers are forced to battle assumptions that they are slow learners and are baffled by technology.

Elevance Health (ELV) has returned more than 40% over the past six months, though it is down 6.5% over the past three while the S&P 500 gained 3.4%. The next leg will not come from selling more insurance. It will come from keeping more of the premium it already collects.

CVS is benefiting from pharmacy growth, AI investments and a discounted valuation, but reimbursement pressure and regulatory scrutiny remain key risks.

The S&P 500 Index ($SPX ) (SPY ) is down -0.54% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.96%. E-mini S&P futures (ESU26 ) are down -0.50%, and September E-mini Nasdaq futures (NQU26...

CVS Health (NYSE:CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on healthcare cost trends and several 2027 headwinds. Speaking at an investor conference, Chief Financial Of

UnitedHealth (UNH) runs the best operating margin of the three managed care companies in its peer group, and the slowest revenue growth of the three. It also carries a significant valuation premium over its peer, Cigna, trading at more than double its earnings multiple.

CVS Health noted a continuation of "high-trend" medical cost growth at a Wells Fargo investor conference on Wednesday, helping to put a spring in the step of hospital stocks including HCA Healthcare, while souring the mood of managed care investors. Shares of CVS stock came away relatively unscathed, while UnitedHealth slipped and Oscar Health stumbled. CVS management's comments about medical cost trends were brief and vague, while Wells Fargo conference presentations by HCA and Universal Health Services didn't appear to provide updates to Q3 trends since Q2 earnings calls.

Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.

The stock is down about 13% from its 52-week high.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

The shingles vaccine costs nothing under Medicare Part D, yet thousands of beneficiaries walk out of their doctor's office owing hundreds of dollars for the exact same shot. The billing system has a gap, and most patients have no idea it exists until they're already holding the receipt.

CVS Health is advancing Aetna's profitability turnaround, supported by stronger Health Care Benefits results, an improved MBR and operational initiatives.

CVS Health stock has delivered a strong 64.8% return over the past three years, and the current valuation picture is not a clear bargain or a clear stretch. Recent gains sit alongside a mixed value score and fresh headlines around its health insurance and compliance record, which give investors a few moving parts to weigh. The 64.8% three year return highlights how much value the market has already credited to CVS Health, so fresh buyers now have to judge whether that past performance still...

CVS Health (NYSE:CVS) announced that updated 2026-2027 COVID-19 vaccines are now available at CVS Pharmacy and MinuteClinic locations across the United States. The company is offering the new vaccines nationwide, with appointments and walk-in options across its retail and clinic network. CVS Health is integrating COVID-19 shots with other vaccinations, aiming to streamline access to multiple immunizations in a single visit. This kind of broad vaccine rollout highlights how large pharmacy...

A caller on the September 2 episode of Mad Money noted that CVS Health Corporation (NYSE:CVS) is up 21% this year, sports a 3% dividend, and trades at a 28 valuation compared to its 54 average. Pointing to raised guidance, higher price targets, and a massive capital plan, they asked if it makes sense to […]

CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CVS Health has outperformed the broader market over the past year, while analysts remain highly bullish on its future prospects.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 23.2% over the past six months, topping the S&P 500 by 11.5 percentage points.

UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.

The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.

The founders of Kemo Sabe, Slick Chicks, Sunhome Saunas and more share important lessons on surviving year one in small business. Plus, everything you need to know before the business tax filing extension deadline hits this year.

The founders of Kemo Sabe, Slick Chicks, Sunhome Saunas and more share important lessons on surviving year one in small business. Plus, everything you need to know before the business tax filing extension deadline hits this year.